View Rule

DoD will finalize the provisions of the published interim final rule. Section 702 of the National Defense Authorization Act for Fiscal Year 2018 (NDAA FY18) makes significant changes to the TRICARE Pharmacy Benefits Program. Specifically, it updates co-payment requirements; authorizes a new process for encouraging use of pharmaceutical agents that provide the best clinical effectiveness by excluding coverage for particular pharmaceutical agents that provide very little or no clinical effectiveness relative to similar agents and for giving preferential status to agents that provide enhanced clinical effectiveness; and authorizes special reimbursement methods, amounts, and procedures to encourage use or high-value products and discourage use of low-value products with respect to pharmaceutical agents provided as part of medical services from authorized providers. This rule was issued as an interim final rule in order to implement expeditiously the reforms authorized by section 702, as specifically authorized by subsection (b)(3) of that section.